Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Men

 Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Men

Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Men

Shots:

  • The P-III ARCHES trial involves assessing of Xtandi + ADT (enzalutamide, 160mg) vs ADT monothx in 1,150 men with mHSPC at the US, Canada, EU, South America
  • P-III ARCHES study results: reducing the risk of radiographic progression or death by 61%; reduced the risk of PSA progression, antineoplastic therapy & deterioration in urinary symptoms; Undetectable PSA (68.1% vs 17.6%); ORR (83.1% vs 63.7%); GRADE 3 or 4 AEs (23.6% vs 24.7%)
  • Xtandi (enzalutamide) is an androgen receptor inhibitor targeted for astration-resistant prostate cancer. In Oct 2009, Pfizer & Astellas globally collaborated to jointly develop & commercialize enzalutamide in the US

Click here to read full press release/ article | Ref: Astellas | Image: Financial Times

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post